Coramaze Technologies Awarded EIC Accelerator Grant and Equity Investment to Advance Tripair™ Toward Pivotal

Coramaze Technologies has been awarded an EIC Accelerator blended financing by the European Innovation Council (EIC), comprising a grant matched by equity investment from the EIB Fund, established by the European Commission. 

The EIC Accelerator is one of Europe’s most selective funding programs for breakthrough innovation. Companies are evaluated across scientific excellence, technological differentiation, execution capability, and potential for meaningful clinical and societal impact. Coramaze is among a cohort of European life science companies selected through the program in 2026. 

The funding will be used to advance Tripair™ through global feasibility clinical studies and to prepare for pivotal trial initiation. 

The problem Tripair™ is built to solve 

Tricuspid regurgitation is one of the most prevalent and most difficult to treat conditions in cardiovascular medicine. An estimated 318,000 patients in the EU and US develop severe or greater TR each year. The disease occurs when the leaflets of the tricuspid valve do not close properly, creating a gap and allowing blood to leak back from the heart into the body. It is independently associated with increased mortality, progressive right-sided heart failure, and severely reduced quality of life. 

The treatment gap is significant. Surgery carries operative mortality rates of 9–12% for isolated tricuspid procedures, with high recurrence rates thereafter. The vast majority of patients are managed with diuretics alone, a strategy that addresses symptoms but does not alter the course of disease. Transcatheter therapies have begun to emerge, but current devices reach only 3% of the eligible population. Procedural complexity, advanced imaging requirements, long procedure times, and anatomical constraints limit their use to a narrow subset of patients at highly specialized centers. 

Over 90% of patients with severe TR have no access to effective structural intervention. For most of them, there is currently no good option. 

Tripair™: enabling simplicity as a design principle 

Tripair™ is a permanent heart implant that anchors atraumatically in the right atrium and takes an edge-to-spacer approach to tricuspid repair. A non-rigid, self-centering spacer enables the tricuspid leaflets to coapt against the spacer surface and close the regurgitant gap. The system is anatomy-agnostic, fully retrievable, and designed for deployment in approximately 30 minutes. 

Simplicity is not a secondary feature of Tripair™: it is the core design principle. Existing transcatheter therapies demand advanced imaging infrastructure, highly specialized teams, and lengthy procedures that limit cath-lab throughput and restrict adoption to a small number of elite centers. Tripair™ is designed to change that dynamic, reducing procedural complexity so that more interventionalists can offer treatment, and more patients can receive it. The goal is not to serve the few patients who already have access. It is to reach the many who do not. 

What the EIC award means 

The EIC Accelerator, part of the European Commission’s Horizon Europe program, provides blended finance combining non-dilutive grant support with equity co-investment from the EIC Fund. It is reserved for companies that demonstrate both scientific excellence and a credible, scalable path to market. Inclusion in the program reflects recognition that the problem Tripair™ addresses is a European, and global, public health priority. 

Looking ahead 

Tripair™ will be evaluated in clinical studies under a global harmonized feasibility protocol in preparation for pivotal trial initiation. This EIC award accelerates that timeline. We will share further updates as clinical milestones approach. 

Tripair™ is an investigational device and is not yet approved for commercial use.